ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1361

Effect of Zen/Doria Remission and Glucocorticoid Dosage on the Pregnancy Outcome of SLE: Retrospective Study in Two Japanese Tertiary Referral Centers

Takehiro Nakai1, Nanase Honda2, Sho Fukui3, Ayako Kitada1, Naoto Yokogawa4 and Masato Okada1, 1St. Luke's International Hospital, Tokyo, Japan, 2Tokyo Metropolitan Tama Medical Center, Fuchu-shi, Japan, 3Brigham and Women's Hospital, Boston, MA, 4Tokyo Metropolitan Tama Medical Center, Taito City, Tokyo, Japan

Meeting: ACR Convergence 2023

Keywords: Disease Activity, glucocorticoids, pregnancy, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1345–1364) Reproductive Issues in Rheumatic Disorders Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Achieving remission is one of the treatment targets in the lupus care and it is also important in preventing the prevalence of adverse pregnancy outcomes (APO).

Although there are reports on relationship with LLDAS/DORIS remission and APOs, little is known on the relationship with Zen/Doria remission and APO, so we conducted this study. In addition, we aimed to investigate optimal cutoff glucocorticoid dosage to predict APO prevalence.

Methods: Pregnant with SLE who was followed up at two Japanese tertiary referral centers were included in our study. We divided the patients into two groups according to the achievement of Zen/Doria remission at conception and analyzed the APO prevalence. Furthermore, we investigated the optimal glucocorticoid dosage to minimize APO.

Results: Of the 124 pregnancies, 59 achieved Zen/Doria remission at conception. Baseline characteristics except for glucocorticoid dosage and hydroxychloroquine usage at conception did not differ according to the achievement of Zen/Doria remission. (remission vs not on remission; prednisolone (PSL): 4.0 [0.0, 5.0] mg/day vs 10.0 [8.0, 11.0] mg/day, p< 0.01, hydroxychloroquine: 54.2% vs 37.8%, p=0.14)

Pregnant on Zen/Doria remission showed significant decrease in the APO ratio compared with those without. (overall APO: OR 0.27, 95%CI 0.11-0.65, p< 0.01, maternal APO: OR 0.34, 95%CI 0.13-0.85, p=0.02, neonatal APO: OR 0.36, 95%CI 0.16-0.85, p=0.02, PROMISSE APO: OR 0.69, 95%CI 0.26-1.8, p=0.45)

On the other hand, glucocorticoid dose of prednisolone equivalent≥7.5mg/day at conception was associated with the increase in APO prevalence. (overall APO: OR 2.36, 95%CI 1.07-5.28, p=0.03, maternal APO: OR1.51, 95%CI 0.66-3.44, p=0.33, neonatal APO: OR 2.69, 95%CI 1.22-5.94, p=0.01, PROMISSE APO: OR 1.62, 95%CI0.68-3.89, p=0.28)

ROC curve also showed that prednisolone dosage >7.5mg/day was related to the decrease in live birth rate (AUC 0.68, 95% CI 0.50-0.85, sensitivity 0.77, specificity 0.62)

Conclusion: Achieving Zen/Doria remission can be a clinical target to reduce APOs in patients who wants to be conceived. In addition, if clinically feasible, reducing glucocorticoid dosage to less than 7.5mg/day before conception can be another treatment target.

Supporting image 1

Table 1: achievement of Zen/Doria remission and its relationship with adverse pregnancy outcome

Supporting image 2

table 2: glucocorticoid dosage and its relationship with adverse pregnanyc outcome

Supporting image 3

Figure 1 Receiver operating characteristic (ROC) curve for glucocorticoid dosage at first trimester to predict each adverse pregnancy outcomes


Disclosures: T. Nakai: None; N. Honda: None; S. Fukui: None; A. Kitada: None; N. Yokogawa: None; M. Okada: AbbVie/Abbott, 6, Eli Lilly, 6, Pfizer, 6.

To cite this abstract in AMA style:

Nakai T, Honda N, Fukui S, Kitada A, Yokogawa N, Okada M. Effect of Zen/Doria Remission and Glucocorticoid Dosage on the Pregnancy Outcome of SLE: Retrospective Study in Two Japanese Tertiary Referral Centers [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/effect-of-zen-doria-remission-and-glucocorticoid-dosage-on-the-pregnancy-outcome-of-sle-retrospective-study-in-two-japanese-tertiary-referral-centers/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-zen-doria-remission-and-glucocorticoid-dosage-on-the-pregnancy-outcome-of-sle-retrospective-study-in-two-japanese-tertiary-referral-centers/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology